VOR vs. SPRY, PRAX, QURE, ATAI, CRON, CRMD, TSHA, IMNM, AMLX, and IOVA
Should you be buying Vor Biopharma stock or one of its competitors? The main competitors of Vor Biopharma include ARS Pharmaceuticals (SPRY), Praxis Precision Medicines (PRAX), uniQure (QURE), atai Life Sciences (ATAI), Cronos Group (CRON), CorMedix (CRMD), Taysha Gene Therapies (TSHA), Immunome (IMNM), Amylyx Pharmaceuticals (AMLX), and Iovance Biotherapeutics (IOVA). These companies are all part of the "pharmaceutical products" industry.
Vor Biopharma vs. Its Competitors
ARS Pharmaceuticals (NASDAQ:SPRY) and Vor Biopharma (NYSE:VOR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.
ARS Pharmaceuticals has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Comparatively, Vor Biopharma has a beta of 2.05, indicating that its stock price is 105% more volatile than the S&P 500.
In the previous week, Vor Biopharma had 7 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 12 mentions for Vor Biopharma and 5 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.94 beat Vor Biopharma's score of 0.19 indicating that ARS Pharmaceuticals is being referred to more favorably in the media.
68.2% of ARS Pharmaceuticals shares are held by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are held by institutional investors. 33.5% of ARS Pharmaceuticals shares are held by company insiders. Comparatively, 0.5% of Vor Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
ARS Pharmaceuticals presently has a consensus target price of $32.50, indicating a potential upside of 226.31%. Vor Biopharma has a consensus target price of $6.07, indicating a potential upside of 279.17%. Given Vor Biopharma's higher possible upside, analysts clearly believe Vor Biopharma is more favorable than ARS Pharmaceuticals.
ARS Pharmaceuticals has higher revenue and earnings than Vor Biopharma. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks.
Vor Biopharma has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -42.74%. Vor Biopharma's return on equity of 0.00% beat ARS Pharmaceuticals' return on equity.
Summary
Vor Biopharma beats ARS Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get Vor Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vor Biopharma Competitors List
Related Companies and Tools
This page (NYSE:VOR) was last updated on 9/16/2025 by MarketBeat.com Staff
Free VOR Stock Alerts